QIAGEN and ID Solutions Partner to Expand Oncology dPCR Assay Portfolio on QIAcuity Platform

Partnership designed to expand QIAGEN’s leadership in oncology-focused digital PCR assays, advancing QIAcuity as the platform of choice for can...

May 23, 2025 | Friday | News
Astellas and Pfizer’s XTANDI Demonstrates 30% Reduced Risk of Death at Five Years in mHSPC Patients

Astellas Pharma Inc. (TSE: 4503) and Pfizer Inc. (NYSE: PFE)  announced compelling five-year overall survival (OS) results from the open-label exten...

May 23, 2025 | Friday | News
Xuanzhu Biopharma’s Bireociclib Approved by NMPA Marks Breakthrough in Advanced Breast Cancer Treatment in China

National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets (tra...

May 16, 2025 | Friday | News
Invenra Launches T-Body™ Trispecific Antibody Platform to Advance Next-Gen Multispecific Therapeutics

Invenra Inc., a pioneer in multispecific antibody discovery and development, announces the launch of its T-Body™ trispecific antibody platform, a n...

May 14, 2025 | Wednesday | News
Exelixis Advances Invenra-Discovered XB628 into Phase 1 Clinical Trial for Solid Tumors

Invenra Inc., a biotechnology company specializing in the discovery and development of multispecific antibodies,  announced that its collaboration par...

May 14, 2025 | Wednesday | News
Hovione and Firstgene Partner to Advance Precision Gene Therapy for Liver Cancer Using Novel AAV-Like Vector Platform

Exclusive licensing and R&D collaboration accelerate the development of a novel gene vector platform for precision gene therapy in Hepatocellular Car...

May 07, 2025 | Wednesday | News
“Too Quiet to Fund?” Jude Research Reveals Bladder Cancer Is One of the UK's Most Underfunded Major Cancers

  To mark Bladder Cancer Awareness Month this May, bladder health brand Jude has conducted new research into how much charitable funding is allocat...

May 06, 2025 | Tuesday | Reports
Australia’s Immutep Achieves 17.6-Month Survival with Chemo-Free Immunotherapy in Head and Neck Cancer

Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS...

May 06, 2025 | Tuesday | News
Can-Fite Secures $175M to Advance Oral A3AR Therapies into Phase III for Liver Cancer and Psoriasis

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases, toda...

May 06, 2025 | Tuesday | News
Crown Bioscience Extends Exclusive Partnership with NEXT Oncology to Advance Translational Cancer Research

Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corp...

May 02, 2025 | Friday | News
InnoCare’s Zurletrectinib Granted Priority Review in China for NTRK Fusion-Positive Tumors

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced that its new generation...

May 02, 2025 | Friday | News
Nuvalent Publishes First-Ever Crystal Structure of ROS1 G2032R, Supporting Rational Design of Zidesamtinib

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinical...

May 01, 2025 | Thursday | News
Innovent Biologics Doses First Patient in Global Phase 1 Trial of IBI3020, First-in-Class Dual-Payload CEACAM5 ADC

Innovent Biologics, Inc. ("Innovent"), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for t...

May 01, 2025 | Thursday | News
Accent Therapeutics Unveils Promising Preclinical Data on First-in-Class Cancer Therapeutics ATX-559 and ATX-295 at AACR 2025

 Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel, targeted, small molecule cancer therapeutics, announced new preclin...

April 29, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close